S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 22 of 22

Issue Date	Title / Author(s) / Citation	File
2015-07	Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review Park, Joon Oh; Oh, Do-Youn; Hsu, Chiun; Chen, Jen-Shi; Chen, Li-Tzong; Orlando, Mauro; Kim, Jong Seok; Lim, Ho Yeong Cancer Research and Treatment, Vol.47 No.3, pp.343-361	DOI
2017-10	Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review Chen, Li-Tzong; Oh, Do-Youn; Ryu, Min-Hee; Yeh, Kun-Huei; Yeo, Winnie; Carlesi, Roberto; Cheng, Rebecca; Kim, Jongseok; Orlando, Mauro; Kang, Yoon-Koo Cancer Research and Treatment, Vol.49 No.4, pp.851-868	DOI
2017-12	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Kang, Yoon-Koo; Boku, Narikazu; Satoh, Taroh; Ryu, Min-Hee; Chao, Yee; Kato, Ken; Chung, Hyun Cheol; Chen, Jen-Shi; Muro, Kei; Kang, Won Ki; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn; Minashi, Keiko; Cho, Jae Yong; Tsuda, Masahiro; Chen, Li-Tzong The Lancet, Vol.390 No.10111, pp.2461-2471	DOI
2018-01	Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma Javle, Milind; Lowery, Maeve; Shroff, Rachna T.; Weiss, Karl Heinz; Springfeld, Christoph; Borad, Mitesh J.; Ramanathan, Ramesh K.; Goyal, Lipika; Sadeghi, Saeed; Macarulla, Teresa; El-Khoueiry, Anthony; Kelley, Robin Kate; Borbath, Ivan; Choo, Su Pin; Oh, Do-Youn; Philip, Philip A.; Chen, Li-Tzong; Reungwetwattana, Thanyanan; Van Cutsem, Eric; Yeh, Kun-Huei; Ciombor, Kristen; Finn, Richard S.; Patel, Anuradha; Sen, Suman; Porter, Dale; Isaacs, Randi; Zhu, Andrew X.; Abou-Alfa, Ghassan K.; Bekaii-Saab, Tanios Journal of Clinical Oncology, Vol.36 No.3, pp.276-282	DOI
2020-01	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer Satoh, Taroh; Kang, Yoon-Koo; Chao, Yee; Ryu, Min-Hee; Kato, Ken; Cheol Chung, Hyun; Chen, Jen-Shi; Muro, Kei; Ki Kang, Won; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn; Minashi, Keiko; Cho, Jae Yong; Tsuda, Masahiro; Tanimoto, Mitsunobu; Chen, Li-Tzong; Boku, Narikazu Gastric Cancer, Vol.23 No.1, pp.143-153	DOI
2020-02	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study Bang, Yung-Jue; Li, Chung-Pin; Lee, Kyung-Hun; Chiu, Chang-Fang; Park, Joon Oh; Shan, Yan-Shen; Kim, Jun Suk; Chen, Jen-Shi; Shim, Hyun-Jeong; Rau, Kun-Ming; Choi, Hye Jin; Oh, Do-Youn; Belanger, Bruce; Chen, Li-Tzong Cancer Science, Vol.111 No.2, pp.513-527	DOI
2020-05	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Chen, Li-Tzong; Satoh, Taroh; Ryu, Min-Hee; Chao, Yee; Kato, Ken; Chung, Hyun Cheol; Chen, Jen-Shi; Muro, Kei; Kang, Won Ki; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn; Minashi, Keiko; Cho, Jae Yong; Tsuda, Masahiro; Sameshima, Hiroki; Kang, Yoon-Koo; Boku, Narikazu Gastric Cancer, Vol.23 No.3, pp.510-519	DOI
2020-05	Phase i study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer Yoo, Changhoon; Oh, Do-Youn; Choi, Hye Jin; Kudo, Masatoshi; Ueno, Makoto; Kondo, Shunsuke; Chen, Li-Tzong; Osada, Motonobu; Helwig, Christoph; Dussault, Isabelle; Ikeda, Masafumi Journal for ImmunoTherapy of Cancer, Vol.8 No.1, p. e000564	DOI
2021-07	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Boku, Narikazu; Satoh, Taroh; Ryu, Min-Hee; Chao, Yee; Kato, Ken; Chung, Hyun Cheol; Chen, Jen-Shi; Muro, Kei; Kang, Won Ki; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn; Minashi, Keiko; Cho, Jae Yong; Tsuda, Masahiro; Nishiyama, Taihei; Chen, Li-Tzong; Kang, Yoon-Koo Gastric Cancer, Vol.24 No.4, pp.946-958	DOI
2021-10	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study Valle, Juan W.; Vogel, Arndt; Denlinger, Crystal S.; He, Aiwu Ruth; Bai, Li-Yuan; Orlova, Rashida; Van Cutsem, Eric; Adeva, Jorge; Chen, Li-Tzong; Obermannova, Radka; Ettrich, Thomas J.; Chen, Jen-Shi; Wasan, Harpreet; Girvan, Allicia C.; Zhang, Wei; Liu, Jiangang; Tang, Chunlao; Ebert, Philip J.; Aggarwal, Amit; McNeely, Samuel C.; Moser, Brian A.; Oliveira, Joana M.; Carlesi, Roberto; Walgren, Richard A.; Oh, Do-Youn The Lancet Oncology, Vol.22 No.10, pp.1468-1482	DOI
2022-01	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study Kang, Yoon-Koo; Morita, Satoshi; Satoh, Taroh; Ryu, Min-Hee; Chao, Yee; Kato, Ken; Chung, Hyun Cheol; Chen, Jen-Shi; Muro, Kei; Kang, Won Ki; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn; Minashi, Keiko; Cho, Jae Yong; Tsuda, Masahiro; Sameshima, Hiroki; Chen, Li-Tzong; Boku, Narikazu Gastric Cancer, Vol.25 No.1, pp.207-217	DOI
2022-02	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Kang, Yoon-Koo; Chen, Li-Tzong; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Chung, Hyun Cheol; Lee, Keun-Wook; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Chung, Ik-Joo; Yamaguchi, Kensei; Kato, Ken; Sym, Sun Jin; Kadowaki, Shigenori; Tsuji, Kunihiro; Chen, Jen-Shi; Bai, Li-Yuan; Oh, Sung-Yong; Choda, Yasuhiro; Yasui, Hisateru; Takeuchi, Kentaro; Hirashima, Yoshinori; Hagihara, Shunsuke; Boku, Narikazu The Lancet Oncology, Vol.23 No.2, pp.234-247	DOI
2023-01	Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma Goyal, Lipika; Meric-Bernstam, Funda; Hollebecque, Antoine; Valle, Juan W.; Morizane, Chigusa; Karasic, Thomas B.; Abrams, Thomas A.; Furuse, Junji; Kelley, Robin K.; Cassier, Philippe A.; Kluempen, Heinz-Josef; Chang, Heung-Moon; Chen, Li-Tzong; Tabernero, Josep; Oh, Do-Youn; Mahipal, Amit; Moehler, Markus; Mitchell, Edith P.; Komatsu, Yoshito; Masuda, Kunihiro; Ahn, Daniel; Epstein, Robert S.; Halim, Abdel-Baset; Fu, Yao; Salimi, Tehseen; Wacheck, Volker; He, Yaohua; Liu, Mei; Benhadji, Karim A.; Bridgewater, John A. New England Journal of Medicine, Vol.388 No.3, pp.228-239	DOI
2023-02	INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG) Lam, Lyn Ley; Pavlakis, Nick; Shitara, Kohei; Sjoquist, Katrin M.; Martin, Andrew J.; Yip, Sonia; Kang, Yoon-Koo; Bang, Yung-Jue; Chen, Li-Tzong; Moehler, Markus; Bekaii-Saab, Tanios; Alcindor, Thierry; O'Callaghan, Christopher J.; Tebbutt, Niall C.; Hague, Wendy; Chan, Howard; Rha, Sun Young; Lee, Keun-Wook; Gebski, Val; Jaworski, Anthony; Zalcberg, John; Price, Timothy; Simes, John; Goldstein, David BMC Cancer, Vol.23 No.1, p. 12885	DOI
2023-02	INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG) Lam, Lyn Ley; Pavlakis, Nick; Shitara, Kohei; Sjoquist, Katrin M.; Martin, Andrew J.; Yip, Sonia; Kang, Yoon-Koo; Bang, Yung-Jue; Chen, Li-Tzong; Moehler, Markus; Bekaii-Saab, Tanios; Alcindor, Thierry; O’Callaghan, Christopher J.; Tebbutt, Niall C.; Hague, Wendy; Chan, Howard; Rha, Sun Y.; Lee, Keun-Wook; Gebski, Val; Jaworski, Anthony; Zalcberg, John; Price, Timothy; Simes, John; Goldstein, David BMC Cancer, 23(1):180	view file DOI
2023-11	Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer Oh, Do-Youn; He, Aiwu Ruth; Qin, Shukui; Chen, Li-Tzong; Okusaka, Takuji; Vogel, Arndt; Kim, Jin Won; Suksombooncharoen, Thatthan; Lee, Myung Ah; Kitano, Masayuki; Burris, Howard; Bouattour, Mohamed; Tanasanvimon, Suebpong; McNamara, Mairead G.; Zaucha, Renata; Avallone, Antonio; Tan, Benjamin; Cundom, Juan; Lee, Choong-Kun; Takahashi, Hidenori; Ikeda, Masafumi; Chen, Jen-Shi; Wang, Julie; Makowsky, Mallory; Rokutanda, Nana; Żotkiewicz, Magdalena; Kurland, John F.; Cohen, Gordon; Valle, Juan W. Future oncology (London, England), Vol.19 No.34, pp.2277-2289	DOI
2024-04	A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors Garmezy, Benjamin; Borad, Mitesh J.; Bahleda, Rastilav; Perez, Cesar A.; Chen, Li-Tzong; Kato, Shumei; Oh, Do-Youn; Severson, Paul; Tam, Betty Y.; Quah, Cheng S.; Harding, James J. Cancer research communications, Vol.4 No.4, pp.1165-1173	DOI
2024-08	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer Chen, Li-Tzong; Vogel, A.; Hsu, C.; Chen, M. -h.; Fang, W.; Pangarsa, E. A.; Sharma, A.; Ikeda, M.; Park, J. O.; Tan, C. K.; Regala, E.; Tai, D.; Tanasanvimon, S.; Charoentum, C.; Chee, C. E.; Lui, A.; Sow, J.; Oh, Do Youn; Ueno, M.; Ramaswamy, A.; Jeo, W. S.; Zhou, J.; Curigliano, G.; Yoshino, T.; Bai, L. -y.; Pentheroudakis, G.; Chiang, N. -j.; Cervantes, A.; Chen, J. -s.; Ducreux, M. Esmo Open, Vol.9 No.8, p. 103647	DOI
2024-08	Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study Oh, Do-Youn; He, Aiwu Ruth; Bouattour, Mohamed; Okusaka, Takuji; Qin, Shukui; Chen, Li-Tzong; Kitano, Masayuki; Lee, Choong-kun; Kim, Jin Won; Chen, Ming-Huang; Suksombooncharoen, Thatthan; Ikeda, Masafumi; Lee, Myung Ah; Chen, Jen-Shi; Potemski, Piotr; Burris, Howard A; Ostwal, Vikas; Tanasanvimon, Suebpong; Morizane, Chigusa; Zaucha, Renata E; McNamara, Mairéad G; Avallone, Antonio; Cundom, Juan E; Breder, Valeriy; Tan, Benjamin; Shimizu, Satoshi; Tougeron, David; Evesque, Ludovic; Petrova, Mila; Zhen, David B; Gillmore, Roopinder; Gupta, Vineet Govinda; Dayyani, Farshid; Park, Joon Oh; Buchschacher, Gary L; Rey, Felipe; Kim, Hyosung; Wang, Julie; Morgan, Claire; Rokutanda, Nana; Żotkiewicz, Magdalena; Vogel, Arndt; Valle, Juan W The Lancet Gastroenterology & Hepatology, Vol.9 No.8, pp.694-704	DOI
2024-08	Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Kang, Yoon-Koo; Terashima, Masanori; Kim, Young-Woo; Boku, Narikazu; Chung, Hyun Cheol; Chen, Jen-Shi; Ji, Jiafu; Yeh, Ta-Sen; Chen, Li-Tzong; Ryu, Min-Hee; Kim, Jong Gwang; Omori, Takeshi; Rha, Sun Young; Kim, Tae Yong; Ryu, Keun Won; Sakuramoto, Shinichi; Nishida, Yasunori; Fukushima, Norimasa; Yamada, Takanobu; Bai, Li-Yuan; Hirashima, Yoshinori; Hagihara, Shunsuke; Nakada, Takashi; Sasako, Mitsuru The Lancet Gastroenterology & Hepatology, Vol.9 No.8, pp.705-717	DOI
2024-11	Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial Boku, Narikazu; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Yamaguchi, Kensei; Kato, Ken; Kadowaki, Shigenori; Tsuji, Kunihiro; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Rha, Sun Young; Lee, Keun-Wook; Chung, Ik-Joo; Sym, Sun Jin; Chen, Li-Tzong; Chen, Jen-Shi; Bai, Li-Yuan; Nakada, Takashi; Hagihara, Shunsuke; Makino, Reina; Nishiyama, Eiji; Kang, Yoon-Koo GASTRIC CANCER, Vol.27 No.6, pp.1287-1301	DOI
2024-11	Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer Goyal, Lipika; Meric-Bernstam, Funda; Hollebecque, Antoine; Valle, Juan W.; Morizane, Chigusa; Karasic, Thomas B.; Abrams, Thomas A.; Furuse, Junji; Kelley, Robin Katie; Cassier, Philippe A.; Klumpen, Heinz-Josef; Chang, Heung-Moon; Chen, Li-Tzong; Tabernero, Josep; Oh, Do-Youn; Mahipal, Amit; Moehler, Markus; Komatsu, Yoshito; Ahn, Daniel H.; Epstein, Robert S.; Halim, Abdel-Baset; Wacheck, Volker; He, Yaohua; Liu, Mei; Benhadji, Karim A.; Bridgewater, John A. Future Oncology, Vol.20 No.36, pp.2811-2822	DOI